China Monoclonal Antibody Industry Report, 2010-2011
  • July/2011
  • Hard Copy
  • USD $1,800
  • Pages:64
  • Single User License
    (PDF Unprintable)       
  • USD $1,700
  • Code: HM002
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,500
  • Hard Copy + Single User License
  • USD $2,000
      
China has been engaging in the R&D of monoclonal antibody industry for a long time, but still lags far behind the European and American countries in terms of industrialization. In 2010, the market scale of monoclonal antibody drugs in China was no more than around USD340million, while the global sales in the same period hit USD44billion.

Restricted by high technical threshold and the need of huge capital, only a few Chinese enterprises can realize industrialized production of monoclonal antibody drugs. Presently, there are around 10 monoclonal antibody drug manufacturers that have carried clinical trials in China, but only some including Shanghai CP Guojian Pharmaceutical, Beijing Biotech Pharmaceutical Company, Chengdu Huasun Group and Shanghai Meien Biotechnology have launched their products into the market. As of May 2011, a total of 17 monoclonal antibody drugs were approved by SFDA and rolled out into the market, among which, nearly 60% were the imported products.

Monoclonal Antibody Drugs Approved for being Launched in Chinese Market as of 2011
201107002.gif
Source: SFDA; ResearchInChina

Currently, the monoclonal antibody product with the highest value of drug use is Roche’s Rituximab which was introduced to China in 2000, and its market shares in the first three quarters of 2009 reached 36.6%. Another leading monoclonal antibody drug of Roche, Trastuzumab accessed into Chinese market late, but its market share keeps rising in the recent years, and it swept a 22.7% market share in the first three quarters of 2009. In addition, Merck’s monoclonal antibody drug Cetuximab gets used for curing colorectal cancer, and the market shares of this drug got to 22.2%.

The monoclonal antibody market is mainly dominated by the imports, but China’s monoclonal antibody drug sales grows significantly as Shanghai CP Guojian Pharmaceutical and Biotech Pharma have launched its own humanized products with price superiority. For instance, Biotech Pharma’s Nimotuzumab, rolled out into the market only in two years, obtained the sale of over RMB100 million in the second year after being launched in the market.
 
Since monoclonal antibody drugs are supported by national policies, Chinese pharmaceutical companies such as Fosun Pharma, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Hisun Pharmaceutical, SL Pharmaceutical, Kanghong Pharmaceutical, Shenzhen Accord Pharmaceutical, Livzon Pharmaceutical Group, etc are also planning to make more projections into the R&D of monoclonal products. In July of 2010, Fosun Pharma announced in Shanghai its joint funding with the international pharmaceutical corporation Chemo to build up the monoclonal antibody drug project, with the total investments approximating RMB500 million as estimated. Livzon Pharmaceutical plans to associate with its shareholder JoinCare to make joint funding for establishing a monoclonal antibody bio-technology company.
1. Overview of Monoclonal Antibody Industry
1.1 Definition
1.2 Classification
1.3 Technological Development

2. Development Environment 
2.1 International Environment
2.2 Policy Environment
2.3 Industry Environment

3. China’s Monoclonal Antibody Industry Market
3.1 Status Quo
3.2 Market Size
3.3 Supply & Demand
3.4 Competition Pattern
3.5 Prospects
3.5.1 Huge Development Space 
3.5.2 Development Trend of Monoclonal Antibody Drugs: All Humanized Antibody
3.5.3 Expanding Indications of Available Monoclonal Antibody Drugs 
3.5.4 Active R&D 

4. Market Segments in China
4.1 Rituxan
4.2 Herceptin
4.3 Erbitux
4.4 Nimotuzumab
4.5 Etanercept

5. Key Manufacturers Worldwide 
5.1 Roche
5.1.1 Profile
5.1.2 Business in China
5.1.3 Genentech
5.2 Johnson & Johnson
5.2.1 Profile 
5.2.2 Monoclonal Antibody Business
5.2.3 Development Outlook 
5.2.4 Business in China
5.3 Merck
5.3.1 Profile
5.3.2 Monoclonal Antibody Business
5.3.3 Business in China
5.4 Novartis
5.4.1 Profile
5.4.2 Monoclonal Antibody Business
5.4.3 Business in China
5.5 Abbott
5.5.1 Profile
5.5.2 Monoclonal Antibody Business
5.5.3 Business in China

6. Key Manufacturers in China
6.1 Shanghai Lansheng States Kin Pharmaceutical Co., Ltd.
6.1.1 Profile
6.1.2 Shanghai CP Guojian Pharmaceutical Co., Ltd.
6.2 Biotech Pharmaceutical Co., Ltd. (BPL)
6.2.1 Profile 
6.2.2 Competitive Edge
6.2.3 Prospects
6.3 Chengdu Huasun Group Inc., Ltd.   
6.3.1 Profile
6.3.2 Operation
6.3.3 Products
6.4 Shanghai Meien Biotechnology Co., Ltd.
6.4.1 Profile
6.4.2 Products
6.5 Shanghai Asia United Antibody Medical Co., Ltd
6.5.1 Profile
6.5.2 Products
6.6 Zhejiang Hisun Pharmaceutical Co., Ltd.
6.6.1 Profile 
6.6.2 Operation
6.6.3 Prospects 
6.7 Shenzhen Main Luck Pharmaceuticals Inc. 
6.8 Beijing Mabworks Biotech Co., Ltd.
6.8.1 Profile 
6.8.2 Antibody Application Products
6.8.3 Antibody Products amid R&D
6.9 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 
6.9.1 Profile 
6.9.2 Operation
6.9.3 Development 
Applications and Proportions of Monoclonal Antibody in Recent Years
Development Process and Major Events of Monoclonal Antibody
Sales of Monoclonal Antibody Drugs in the World, 2007-2010 
M&A Events Related to Monoclonal Antibody of Biological Product Enterprises Worldwide, As of 2011 
Availability Time of the World's Leading Monoclonal Antibody Drugs and their Sales in 2010  
Innovation Funds for Bio-Industry from the 9th to the 12th Five-Year Plan Periods in China  
Policies Related to Biotechnology Drugs 
Total Industrial Sales and Growth Rate of Biological & Biochemical Products in China, 2008- 2010   
Industrial Bases of Monoclonal Antibody Drugs in China, 2010 
Monoclonal Antibody Drugs Approved for Marketing in China, As of 2011
Sales of Antibody Drugs in China, 2008-2010  
The Purchasing Amount of Main Monoclonal Antibody Drugs in the Typical Hospitals of China’s 22 Cities, 2009 
Causes of Death of Chinese Residents, 2008
Incidence of Malignant Tumor in China, 1993-2008 
Consumption Value Shares of Monoclonal Antibody Drugs, Q1-Q3 2009 
Proportions of Monoclonal Antibody Drugs in Bio-Pharmaceuticals in China and the World, 2008-2010
China's Leading Monoclonal Antibody Drugs under Research, As of 2010
Listed Companies Invested in Monoclonal Antibody Industry in China, 2009-2010
Sales of Rituximab in Sample Hospitals, 2003, 2008 and 2009  
The Purchasing Amount of Rituximab in Typical Hospitals of China’s 3 Major Cities, 2009
Sales and Growth of Trastuzumab (Herceptin) in the World, 2006-2010  
The Purchasing Amount of Trastuzumab in Typical Hospitals of China’s 3 Major Cities, 2009
The Purchasing Amount of Cetuximab in Typical Hospitals of China’s 3 Major Cities, 2009
Sales of Nimotuzumab in China, 2008-2010 
Sales of Etanercept in China, 2006-2010 
The Purchasing Amount of Etanercept in Typical Hospitals of China’s 3 Major Cities, 2009
Revenue and Operating Profit of Roche, 2008-2010 
Major M&A Cases of Roche, 1990-2010
Roche Investment in China
Sales of Major Monoclonal Antibody Products of Genentech in the World, 2007-2010 
Net Sales and Operating Profit of Johnson & Johnson, 2008-2010 
Sales of Infliximab Worldwide, 2007-2010 
Monoclonal Antibody Products of Johnson & Johnson
Sales and Net Revenue of Merck, 2008-2010 
Net Sales and Net Revenue of Novartis, 2008-2010 
Development Process of Pharmaceutical Business of Novartis in China
Net Sales of Abbott, 2007-2010  
Sales of Humira Worldwide, 2007-2010 
Product Line of Major Monoclonal Antibody under Research of Shanghai Lansheng States Kin Pharmaceutical 
Operating Income and Net Income of Shanghai CP Guojian Pharmaceutical, 2008-2010 
Monoclonal Antibody Product Series under Research of Shanghai CP Guojian Pharmaceutical 
Under-research Monoclonal Antibody Projects of BPL
Operating Income and Total Profit of Chengdu Huasun Group, 2007-2010 
Sales and Sales Volume of Metuximab in China, 2007-2010
Liver Cancer Incidence and Death Cases in China and the World, 2000 & 2010 
Operating Income and Gross Margin of Zhejiang Hisun Pharmaceutical, 2001-2010 
Operating Income Structure of Zhejiang Hisun Pharmaceutical by Product, 2010  
Application Antibody Products of Beijing Mabworks Biotech
Under-research Antibody Projects of Beijing Mabworks Biotech
Operating Income and Total Profit of Shanghai Fosun Pharmaceutical (Group), 2008-2010 

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号